KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $5.2 million.

  • Sarepta Therapeutics' Gains from Investment Securities rose 31380.53% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 31380.53%. This contributed to the annual value of $8.9 million for FY2024, which is 728.63% down from last year.
  • Latest data reveals that Sarepta Therapeutics reported Gains from Investment Securities of $5.2 million as of Q3 2025, which was up 31380.53% from -$4.6 million recorded in Q2 2025.
  • Over the past 5 years, Sarepta Therapeutics' Gains from Investment Securities peaked at $36.8 million during Q4 2024, and registered a low of -$5.2 million during Q2 2024.
  • In the last 5 years, Sarepta Therapeutics' Gains from Investment Securities had a median value of $1.1 million in 2023 and averaged $4.0 million.
  • In the last 5 years, Sarepta Therapeutics' Gains from Investment Securities surged by 3590649.35% in 2022 and then tumbled by 56608.75% in 2024.
  • Sarepta Therapeutics' Gains from Investment Securities (Quarter) stood at $77000.0 in 2021, then soared by 35906.49% to $27.7 million in 2022, then plummeted by 98.71% to $357000.0 in 2023, then soared by 10205.6% to $36.8 million in 2024, then crashed by 85.89% to $5.2 million in 2025.
  • Its Gains from Investment Securities was $5.2 million in Q3 2025, compared to -$4.6 million in Q2 2025 and $1.5 million in Q1 2025.